immunomedics
announces
encouraging
clinical
results
brain
cancers
morris
plains
globe
newswire
immunomedics
nasdaq
immu
immunomedics
company
leading
biopharmaceutical
company
area
conjugates
today
announced
trodelvy
delivered
inhibitory
concentration
bmbc
rgbm
respectively
produced
partial
responses
cohorts
brain
cancer
patients
early
intracranial
responses
encouraging
signs
sacituzumab
govitecan
activity
central
nervous
system
cns
tumors
previously
observed
preclinical
models
said
andrew
brenner
clinical
investigator
institute
drug
development
experimental
developmental
therapeutics
program
b
kolitz
endowed
chair
research
mays
cancer
center
ut
health
san
antonio
san
antonio
tx
reported
results
mini
oral
session
cns
tumors
esmo
virtual
congress
hydrolysable
linker
allows
released
tumor
site
given
freely
crosses
blood
brain
barrier
active
nanomolar
range
cancer
cells
including
breast
cancer
tnbc
gbm
sacituzumab
govitecan
prerequisite
ability
deliver
therapeutically
relevant
concentrations
across
undisrupted
vasculature
early
clinical
results
patients
neoplastic
involvement
brain
warrant
development
trodelvy
aggressive
lethal
time
data
cutoff
patients
bmbc
rgbm
enrolled
study
key
clinical
data
evaluable
patients
summarized
new
safety
signals
observed
bmbc
rgbm
tumor
response
n
partial
response
n
ongoing
survival
n
range
days
days
residual
measurable
disease
n
tumor
concentrations
n
mean
total
nm
range
mean
free
nm
range
detected
patient
cohort
nm
per
rano
criteria
glucuronide
inactive
metabolite
brain
metastasis
significant
concern
patients
tnbc
encouraged
study
results
stated
loretta
itri
chief
medical
officer
immunomedics
additionally
given
gbm
disease
great
unmet
need
working
close
collaboration
brenner
others
including
southwestern
oncology
group
design
programs
could
potentially
elucidate
role
trodelvy
management
bmbc
patients
bmbc
rgbm
enrolled
single
center
study
receive
single
intravenous
dose
trodelvy
mg
kg
one
day
surgical
resection
tumor
corresponding
serum
collected
surgery
measure
levels
metabolites
following
recovery
patients
resumed
trodelvy
treatment
mg
kg
days
cycles
assessed
responses
mri
every
third
cycle
using
response
assessment
rano
criteria
brain
cancer
according
national
cancer
institute
nci
estimated
american
diagnosed
brain
cancer
people
die
disease
among
numerous
brain
tumor
types
glioblastoma
gbm
aggressive
median
survival
pfs
median
overall
survival
os
diagnosis
months
months
respectively
reported
clinical
patients
recurrent
gbm
chemotherapy
regimens
associated
overall
response
rates
pfs
median
os
references
pandey
r
gruslova
chiou
j
et
al
stable
isotope
dilution
assay
determine
free
total
tumor
xenograft
model
intravenous
administration
conjugate
sacituzumab
govitecan
anal
chem
https
statfacts
html
accessed
september
stupp
r
mason
wp
van
den
bent
mj
et
al
european
organisation
research
treatment
cancer
brain
tumor
radiotherapy
groups
national
cancer
institute
canada
clinical
trials
group
radiotherapy
plus
concomitant
adjuvant
temozolomide
glioblastoma
n
engl
j
med
gilbert
mr
dignam
jj
armstrong
ts
et
al
randomized
trial
bevacizumab
newly
diagnosed
glioblastoma
n
engl
j
med
gilbert
mr
wang
aldape
kd
et
al
temozolomide
newly
diagnosed
glioblastoma
randomized
phase
iii
clinical
trial
j
clin
oncol
chinot
ol
wick
w
mason
w
et
al
bevacizumab
plus
newly
diagnosed
glioblastoma
n
engl
j
med
wong
et
hess
kr
gleason
mj
et
al
outcomes
prognostic
factors
recurrent
glioma
patients
enrolled
onto
phase
ii
clinical
trials
clin
oncol
van
den
bent
mj
brandes
aa
rampling
r
et
al
randomized
phase
ii
trial
erlotinib
versus
temozolomide
carmustine
recurrent
glioblastoma
eortc
brain
tumor
group
study
clin
oncol
batchelor
tt
mulholland
p
neyns
b
et
al
phase
iii
randomized
trial
comparing
efficacy
cediranib
monotherapy
combination
lomustine
versus
lomustine
alone
patients
recurrent
glioblastoma
clin
oncol
wick
w
puduvalli
vk
chamberlain
mc
et
al
phase
iii
study
enzastaurin
compared
lomustine
treatment
recurrent
intracranial
glioblastoma
clin
oncol
taal
w
oosterkamp
hm
walenkamp
ame
et
al
bevacizumab
lomustine
versus
combination
bevacizumab
plus
lomustine
patients
recurrent
glioblastoma
belob
trial
randomised
controlled
phase
trial
lancet
oncol
immunomedics
immunomedics
leader
conjugate
adc
technology
committed
help
transform
lives
people
cancers
proprietary
adc
platform
centers
using
novel
linker
require
enzyme
release
payload
deliver
active
drug
inside
tumor
cell
tumor
microenvironment
thereby
producing
bystander
effect
trodelvy
lead
adc
first
adc
fda
approved
treatment
people
metastatic
breast
cancer
also
first
adc
additional
information
company
please
visit
website
https
information
website
however
form
part
press
release
cautionary
note
regarding
statements
release
addition
historical
information
may
contain
statements
made
pursuant
private
securities
litigation
reform
act
statements
including
statements
regarding
expectations
achieving
full
fda
approval
based
confirmatory
data
trodelvy
company
development
trodelvy
additional
indications
clinical
trials
including
funding
therefor
anticipated
patient
enrollment
trial
outcomes
timing
associated
costs
regulatory
applications
related
timelines
including
filing
approval
timelines
blas
bla
supplements
arrangements
forecasts
future
operating
results
potential
collaborations
capital
raising
activities
timing
bringing
product
candidate
market
involve
significant
risks
uncertainties
actual
results
could
differ
materially
expressed
implied
herein
factors
could
cause
differences
include
limited
company
reliance
relationships
outsourcing
arrangements
example
connection
manufacturing
logistics
distribution
sales
marketing
may
always
full
control
including
failure
third
parties
company
dependent
meet
company
business
operational
needs
investigational
commercial
products
comply
company
agreements
laws
regulations
impact
company
company
ability
meet
compliance
obligations
topics
including
limited
product
quality
product
distribution
supply
chain
requirements
promotional
marketing
compliance
imposition
significant
regulatory
requirements
products
including
requirement
confirmatory
clinical
study
failure
maintain
obtain
full
regulatory
approval
company
products
received
due
failure
satisfy
regulatory
requirements
submission
sufficient
data
confirmatory
clinical
uncertainties
inherent
research
development
safety
efficacy
concerns
related
company
products
product
uncertainties
rate
degree
market
acceptance
products
product
candidates
inability
create
effective
direct
sales
marketing
infrastructure
partner
third
parties
offer
infrastructure
distribution
company
products
product
candidates
inaccuracies
company
estimates
size
potential
markets
company
products
product
candidates
limitations
regulators
proposed
treatment
population
company
products
product
decisions
regulatory
authorities
regarding
labeling
matters
could
affect
availability
commercial
potential
company
products
product
candidates
company
dependence
business
collaborations
availability
required
financing
capital
markets
sources
acceptable
terms
order
develop
products
finance
operations
new
product
development
including
clinical
trials
outcome
regulatory
requirements
actions
risk
collaborators
may
unable
secure
regulatory
approval
market
drug
candidates
risks
relating
pandemic
around
world
risks
associated
litigation
company
may
become
party
including
cost
potential
reputational
damage
resulting
litigation
loss
key
personnel
competitive
risks
marketed
products
company
ability
repay
outstanding
indebtedness
required
well
risks
discussed
company
filings
securities
exchange
commission
company
obligation
company
expressly
disclaims
obligation
update
alter
statements
whether
result
new
information
future
events
otherwise
information
chau
cheng
ccheng
media
inquiries
darren
opland
darren
